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A B S T R A C T
The aim of this study was to examine the effect of cyclic adenosine monophosphate (cAMP) and its possible interfer-
ence/synergism with calcium channel blocker in mice with acute liver injury induced with D-galactosamine (D-GalN)
and lipopolysaccharide (LPS). C57Bl/6 mice were given i.p. simultaneously 300 mg/kg D-GalN and LPS 0.01 mg/kg.
This treatment induced severe hepatitis, as evidenced by high mortality (80–90%) of control mice and large increase in
concentration of aminotransferases in plasma (AST, ALT). Injection of stabile analogue of cAMP (dibutyryl-cAMP, db-
-cAMP) one hour before hepatotoxic agents increased survival of mice in dose-dependent manner and in medium dose
significantly decreased plasma ALT level. Similar (protective) effect had also verapamil, calcium channel blocker, when
given in non toxic doses and at the same time schedule as db-cAMP. Combination of db-cAMP and verapamil had not
synergistic effect in protection from D-GalN+LPS hepatotoxicity; the survival of mice was similar to that seen in protec-
tion caused by each agent alone.
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Introduction
Liver failure (damage) is frequently final result of
liver infections and severe complication of highly mortal-
ity diseases, like sepsis1. Various experimental models
are used to study the mechanisms of liver damage in in-
fection diseases involving liver, which generally include
the agent that is hepatotoxic per se and/or blocks the pro-
cess of transcription in endogenous protein synthesis,
specifically in liver (D-galactosamine – D-GalN) or in
general (actinomycine D – Act D), and the agent which
stimulates the synthesis or accumulation of inflamma-
tory mediators in liver2,3. Among the latter agents, most
frequently used are: the active component of endotoxin
from gram-negative bacteria – lipopolysaccharide (LPS),
T-cell mitogenes – Concanavalin A (Con A) or phytohe-
magglutinin (PHA), bacteries Corynebacterium parvum
(CP), exogenously administered mediators in D-GalN
sensitized mice, etc.
Various inflammatory mediators, depending on its na-
ture, may have either noxious (pathogenic) or protective
effect on liver damage in these models. Thus, tumor ne-
crosis factor-alpha (TNF-a) is well proven to be patho-
genic in mice given LPS+D-GalN, since administration
of monoclonal antibodies to this cytokine greatly reduced
liver damage (as assessed by reduction of animal mortal-
ity, serum aminotransferase level, and histopathological
damage)4–6. Similar effects were obtained in transgenic
mice with nonfunctional gene for TNF-a or its type 2
receptor7. Also interferon-g (IFN-g) appears to mediate
liver damage in this model as well as in hepatotoxicity in-
duced with Con A+D-GalN or with D-GalN alone8. The
data also show that IL-1 and IL-6 can mediate liver
toxicity9. The results obtained with stimulation of syn-
thesis or inhibiting of action of nitric oxide (NO) are
controversial10–12. Prostaglandin of series E (PGE1 or
PGE2) were shown to be protective in different »infec-
tion like« models of hepatic damage13,14, as well as in
hepatotoxicity induced by acetaminophen15. On the con-
trary, it was shown in one experiment that thromboxane
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A2 might mediate liver damage in mice intoxicated with
TNF-a+ D-GalN16. As one would expect, generally sup-
pressive cytokine, IL-10, alleviated liver damage in sev-
eral models of hepatotoxicity when it was administered
exogenously or is produced in increase quantity when the
synthesis of TNF-a or its actions were blocked9.
Agents that raise the level of cyclic adenosine mono-
phosphate (cAMP), which is known for its general anti-
-inflammatory or immunosuppressive actions, have gen-
erally beneficial (protective) effect in described models of
hepatic damage. By analyzing the mortality of mice, se-
rum aminotransferase concentrations, level of histopa-
thological damage by classical means or by the level of
apoptosis in liver and/or liver-production of TNF-a, it
was shown that inhibitors of cAMP breakdown (espe-
cially inhibitors of type IV phosphodiesterase)17,18 and
stimulators of adenylyl cyclase18 have protective effect on
hepatitis induced by LPS, Con A or TNF-a in D-GalN
sensitized mice. Similar protective effect was obtained by
use of stabile, cell permeable analogue of cAMP (dibuty-
ryl-cAMP, db-cAMP)19. In model of acute hepatotoxicity
induced with acetaminophen, we and others have shown
that PGE2 as well as IL-1 and IL-6 have hepatoprotective
effect20–22. Similar effect was shown with PGI223. Since it
is known that PGE2, IL-6, and PGI2 increase the synthe-
sis of cAMP in many cells, the increase of cAMP in liver
cells might be common pathway for protective effect of
these prostaglandins and inflammatory cytokines aga-
inst APAP toxicity.
It is known that many hepatotoxicants cause the rise
of concentration of intracellular calcium, which inter-
feres with many important cellular reactions, leading fi-
nally to cell death24,25. Indeed, administration of cal-
cium channel blocker (verapamil) alleviated the hepato-
toxicity in mice given lethal dose of TNF-a or LPS26,27.
However, it appears that the rise of concentration of
intracellular calcium mediates apoptotic but not ne-
crotic death of hepatocytes28. The possible effect of in-
creased intracellular level of calcium on cAMP – activity
is largely unknown.
In these experiments we investigated the effect of
db-cAMP and verapamil on liver injury in mice induced
by simultaneous application of D-GalN and LPS, when
they were administered separately or combined (in order
to see if they might have synergistic or antagonistic effect).
Materials and Methods
Animals
C57Bl/6 mice were raised in an animal colony unit at
the Department of Physiology, School of Medicine, Zag-
reb. Mice of both sexes aged 12–16 weeks and weighing
20–25 g were used in all experiments. In particular ex-
periment, only mice of the same sex were used. The cages
were stored in rooms with a 12h light period from 6 a.m.
to 6 p.m., and the temperature and relative humidity in
the animal room were 21±2°C and 50±5%, respectively.
The cages were sanitized twice weekly. All mice were
given free access to tap water and standard mouse chow
diet (Diete Standard, Milano, Italy).
Chemicals
Db-cAMP – Cat. No. A9501, LPS from Escherichia
coli (strain 0111 : B4) – Cat. No. L2630, and D-galactosa-
mine – Cat. No. G0500, were purchased from Sigma-
-Aldrich (St Louis, USA). Verapamil (calcium channel
blocker, ampoules for human use, 2 mL/5 mg) was ob-
tained from Belupo (Koprivnica, Croatia).
Induction of hepatitis with D-GalN and LPS
In our previous experiments20 mice were given i.p.
route 650 mg/kg of D-GalN and 0.01 mg/kg (0.2 mg/
mouse) of LPS. This caused 100% mortality of control
mice and almost all animals died within 10 hours. There-
fore, in order to reduce or delay the morality of mice we
tested lower dose of D-GalN. In these experiments we in-
jected to mice 300 mg/kg of D-GalN and the same dose of
LPS (0.01 mg/kg, 0.2 mg/mouse). Both agents were given
simultaneously, i.p., in volume of 0.2 to 0.25 mL. Most
animals died within 8 to 16 hours; all animals which sur-
vived 24 hours recovered completely. For bleeding and
determination of aminotransferases, mice were given the
same dose of LPS but the lower dose of D-GalN (150
mg/kg).
Treatment
Db-cAMP was dissolved and verapamil diluted to ap-
propriate concentrations in saline and injected to mice
one hour before D-GalN and LPS i.p. in volume of 0.2 to
0.25 mL. Experimental and control groups of mice con-
taited 10–12 animals (for determining survival of ani-
mals) or 6–8 animals (for determining ALT and AST ac-
tivity). Control animals received appropriate vehicle.
Plasma ALT and AST activity
ALT and AST levels were measured 20–22h after
D-Galn+LPS administration. Plasma samples were ob-
tained by a procedure in which hemolysis was undetect-
able. Mice were given 250 U heparin i.p. 15 min before
bleeding. Blood was collected by puncture of the medial
eye angle with heparinized glass capillary tubes. Plasma
was stored at –70°C for 24h before ALT and AST deter-
mination. ALT and AST concentrations were measured
by standard diagnostic laboratory techniques20.
Statistical analysis
Results are expressed as mean±SEM. Parametric va-
riables were compared by Student’s t-test. Differences in
survival between groups of mice were compared by chi-
-square test, using Yates’s correction of the test when in-
dicated.
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Results
The effects of db-cAMP on survival of mice given
LPS sensitized with D-GalN
In two separate experiments mice were given differ-
ent doses of db-cAMP (5 mg/kg, 25 mg/kg and 125 mg/kg)
one hour before LPS+D-GalN. Control mice obtained sa-
line instead cAMP. There were 22 to 23 animals per
group. Figure 1 shows the summary survival of mice ob-
tained in two experiments. We can see that cAMP in-
creased the survival of animals in dose-dependent man-
ner. The survival of mice at the dose 125 mg/kg cAMP
was significant in comparison to control group given sa-
line (p<0.05), while the survival at the dose 25 mg/kg
cAMP was on the verge of significance (p=0.047). Since
at the dose 125 mg/kg cAMP three animals died immedi-
ately after its administration, we considered this dose as
toxic one, and the dose 25 mg/kg cAMP was used in fur-
ther experiments.
The effects of db-cAMP on concentration of
aminotransferases in plasma of mice given
D-GalN+LPS
Saline or 25 mg/kg db-cAMP were given to mice which
one hour latter received 150 mg/kg D-GalN and 0.2
mg/mouse LPS. Concentrations of AST and ATL were
determined 21 h thereafter (Table 1). As seen, in com-
parison to normal (non-treated) mice, administration of
D-GalN+LPS greatly increased plasma concentrations
of both AST and ALT. Treatment with db-cAMP de-
creased partially this rise of aminotransferase level, in
the case of ALT significantly (p<0.05).
The effects of calcium channel blocker–verapamil
on concentration of ALT in plasma of mice given
D-GalN+LPS
Verapamil at three different doses (5 mg/kg, 20 mg/kg
or 80 mg/kg) was injected to mice one hour before they re-
ceived D-GalN+LPS (150 mg/kg D-GalN and 0.2 mg/
mouse LPS). Concentration of ALT was determined 20–22
hours after that. Summary results of two different exper-
iments are shown in Figure 2. As seen, when injected in
two lower doses (5 mg/kg and 20 mg/kg), verapamil de-
creased significantly the concentration of ALT in com-
parison to mice given saline before hepatotoxic agents.
On the other hand, high dose of the drug (80 mg/kg) ap-
pears to be toxic, since almost half animals died in half to
one hour after treatment and level of ALT in survived an-
imals was higher than in controls.
The effects of verapamil on survival of mice
given D-GalN+LPS
In this experiment only one dose of verapamil was
tested – 10 mg/kg. As in previous experiments, verapamil
was given one hour before D-GalN (300 mg/kg) + LPS.
Figure 3 shows that verapamil increased the survival of
intoxicated animals, but (probably due to low number of
animals in groups, 10 mice in each group) the difference
was not significant (p=0.06).
















Fig. 1. The survival of mice given different doses of db-cAMP
one hour before simultaneous injection of D-GalN and LPS.
The survival was recorded 24 hours after administration of
D-GalN and LPS. Number of mice: 22–23 per group, except in
group treated with 125 mg/kg cAMP (19 mice). Asterisk indi-
cates significance to mice given saline before D-GalN and LPS
at p<0.05 level.
TABLE 1
THE EFFECT OF DB-cAMP ON PLASMA AMINORNSFERASE
LEVEL IN MICE WITH HEPATITIS INDUCED WITH D-GalN+LPS
Treatmenta AST (U/L)b ALT (U/L)b
Saline 1207.5±201.1 993.3±128.4
db-cAMP (25 mg/kg) 585.3±84.7 516.0±61.75*
Normal (untreated) mice 75.2±4.0 23.1±1.2
a db-cAMP (or saline) were given i.p. one hour before admini-
stration of D-GalN+LPS (300 mg/kg + 0.2 mg/mouse)
b Mean±SE; 8–9 mice per group





















Fig. 2. Effects of verapamil on concentration of ALT in plasma of
mice given D-GalN+LPS. The concentration of ALT was deter-
mined 20–22 hours after administration of D-GalN and LPS.
Shown are the summary results of two different experiments.
Number of mice: 10–12 per group, except in group treated with 80
mg/kg verapamil (6 mice). Asterisk indicates significance to mice
given saline before D-GalN and LPS at p<0.05 level.
The effects of combined treatment with cAMP and
verapamil on survival of mice given
D-GalN+LPS
In the next experiment we checked whether there is
a synergy of cAMP and calcium channel blocker in their
protective effect on liver injury caused by heptotoxi-
cants. Before intoxication with D-GalN (250 mg/kg) and
LPS (0.2 mg/mouse), mice received one hour before 25
mg/kg db-cAMP and half hour before verapamil (10
mg/kg). As seen in Figure 4, it appears that combination
of db-cAMP and verapamil has not synergistic effect in
protection from hepatotoxicity – the survival of mice
was similar to that seen earlier in protection of each
agent alone. However, this effect should be investigated
on higher number of animals and by using different
schedules of application.
Discussion
Cyclic adenosine monophosphate (cAMP, cyclic AMP)
is a second mesenger that is present in almost all cells in
organism and is important in many biological processes.
It is synthesized by enzyme adenylyl cyclase and decom-
posed by enzymes called phosphodiesterases (PDE), of
which type IV of PDE appears to be the most impor-
tant29. Of variety actions of cAMP, the most important
for purpose of this study is its generally inhibitory action
on synthesis and action of proinflammatory cytokines.
This is the main reason that the cAMP or its derivatives
are used clinically for treatment of obstructive and de-
generative diseases in lungs30. In variety experimental
models it was shown that cAMP inhibits production of
proinflammatory cytokines, like TNF-a, IL-1, IFN-y, IL-
-18, etc. Thus, raising its level in cells, by stimulation of
adenylyl cyclase or by inhibition of type IV PDE (espe-
cially by drug rolipram) and less frequently by exogenous
administration of its stabile cell permeable analogue –
db-cAMP, has beneficial effect in many models of liver
toxicity17–19. On the other hand, there are evidences that
it stimulates the production of immunosuppressive cy-
tokines (IL-10) and PGE2, which have similar (suppres-
sive) effect on production of inflammatory cytokines31.
Acute hepatotoxicity induced with D-GalN and LPS is
one of the first experimental models in which the patho-
genic role of TNF-a was proven. Thus, the hepatotoxicity
in mice can be almost completely prevented (and animals
saved) if mice were given monoclonal antibodies to TNF-
-a4–6 or if transgenic mice with nonfunctional TNF-a re-
ceptor (type I) were used7. It was shown that inhibitors
of cAMP breakdown (especially rolipram, inhibitor of
PDE IV)17,18 and stimulators of adenylyl cyclase18,19 in-
hibit production of TNF-a and/or alleviated hepatitis in-
duced by LPS, Con A or TNF-a in D-GalN sensitized
mice. Similar protective effect was obtained by use of sta-
bile, cell permeable analogue of cAMP (dibutyryl-cAMP,
db-cAMP)19. The latter effect was obtained in mice sensi-
tized with D-GalN and pretreated with recombinant
TNF-a – liver injury was assessed by serum amino-
transferase levels and histopathological changes.
In our experiments, using mice in which liver injury
was induced by D-GalN and LPS, we obtained the dose-
-dependent increase in survival of mice pretreated with
db-cAMP (which was significant when the highest dose
of the drug was used – 125 mg/kg) and significant de-
crease of serum ALT concentration (when medium dose
of the drug – 25 mg/kg was used).
It is known that many hepatotoxicants, like aceta-
minophen25,27 as well as TNF-a or LPS in D-GalN sensi-
tized mice16,26 increase concentration of intracellular cal-
cium, which interferes with many important cellular
reactions, leading finally to cell death. Administration of
calcium channel blocker (verapamil) at non-toxic dose al-
leviated the liver injury, as assessed by reduction of
plasma aminotransferase level and by increase of sur-
vival of mice (Figure 2 and 3). Essentially, our results are
in line with those obtained by others16,26.
In our preliminary investigations, we did not obtain
the synergism in hepatoprotective action of db-cAMP
and calcium channel blocker (verapamil) (Figure 4). The
interrelationship of cAMP and intracellular calcium ions

























Fig. 4. Effects of db-cAMP and verapamil on survival of mice gi-
ven D-GalN+LPS. db-cAMP (25 mg/kg) was injected i.p. one hour
and verapamil (10 mg/kg) half hours before D-GalN+LPS. The
survival was recorded 24 hours after administration of D-GalN
and LPS. Number of mice: 10 per group, except in group given





















Fig. 3. Effects of verapamil (10 mg/kg) on survival of mice given
D-GalN+LPS. The survival was recorded 24 hours after admin-
istration of D-GalN and LPS. Number of mice: 10 per group. The
difference to control group given saline was not significant
(p=0.06).
is probably very complex, although in one in vitro experi-
ment it was shown that synthesis of cAMP (and consecu-
tive intracellular signaling) is possible when the cell in-
flux of calcium was blocked25,32. However, the effect of
modulation of intracellular calcium concentration on cell
injury may be very dependent on the time of its modulation
in respect to time of application of noxious liver agent.
In addition, it is necessary to repeat this experiment
with higher number of animals, different time schedules
of drug administration, and by analyzing different end
points of liver injury (histopathology, serum aminotrans-
ferase level, etc.).
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ULOGA CIKLI^NOG ADENOZIN MONOFOSFATA U MODELU AKUTNOG TOKSI^NOG O[TE]ENJA
JETRE D-GALAKTOZAMINOM I LIPOPOLISAHARAIDOM U MI[EVA
S A @ E T A K
Svrha ovog istra`ivanja bila je ispitati u~inak cikli~nog adenozin monofosfata (cAMP) i njegovo mogu}e zajedni~ko
djelovanje/sinergizam s blokatorom kalcijskih kanala u mi{eva u modelu akutnog toksi~nog o{te}enja jetre uzrokova-
nog primjenom D-galaktozamina (D-GalN) i lipopolisaharida (LPS). Pokusi su bili u~injeni na visokosrodnim mi{evima
soja C57Bl/6 kojima su istodobno intraperitonealno (i.p.) u{trcani D-GalN (300 mg/kg) i LPS (0,01 mg/kg). Primjena
ovih hepatotoksi~nih agenasa dovela je do o{te}enja jetre, {to se o~itovalo u visokoj smrtnosti `ivotinja (80–90%) i
velikom porastu jetrenih aminotransferaza u plazmi (ALT i AST) u kontrolnoj skupini mi{eva. U{trcavanje stabilnog
analoga cAMP (dibutiril-cAMP, db-cAMP) jedan sat prije D-GalN i LPS, dovelo je do zna~ajnog pove}anja pre`ivljenja
`ivotinja (u~inak ovisan o dozi) i smanjenja porasta koncentracije ALT u plazmi. Sli~an (protektivni) u~inak ostvario se
primjenom blokatora kalcijskih kanala – verapamila, koji je bio u{trcan mi{evima u netoksi~nim dozama (5 i 20 mg/kg)
te na isti na~in kao i db-cAMP. Kombiniranim davanjem db-cAMP i verapamila u ovom modelu, nije se ostvario o~eki-
vani sinergisti~ki hepatoprotektivni u~inak: nije bilo razlike u pre`ivljenju `ivotinja u odnosu na pojedina~nu primjenu
jednog ili drugog agensa.
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